refractory vs resistant cancer
Castration-Resistant Prostate Cancer Treatment Outlook
· Castrate-resistant prostate cancer is prostate cancer that stops responding to hormone therapy. Hormone therapy also called androgen deprivation
Management of Patients With Resistant or Refractory
23. O Hare T Walters DK Stoffregen EP et al In vitro activity of Bcr-Abl inhibitors AMN107 and BMS against clinically relevant imatinib-resistant Abl kinase domain mutants. Cancer Res 65 2005. 24. Deininger M Buchdunger E Druker BJ The development of imatinib as a therapeutic agent for chronic myeloid leukemia.
Definitions of Resistant and Refractory Cytomegalovirus
· In this article we aim to define refractory and/or resistant CMV infections after SOT or HCT to provide consistent criteria for future clinical trials and outcomes research. Clinical suspicion of drug-resistant CMV infections is usually based on suboptimal responses to antiviral agents leading to a treatment-refractory condition.
Success and failure of additional immune modulators in
to refractory cases (steroid-refractory median 68 days vs resistant median 182 days p=0.02) ( 1D). The figure median time from initial treatment with steroids to treat-ment with additional immune modulator in steroid- refractory patients was 7 days (range 2 to 23 days 10/12 patients treated in <14 days). In patients with resistant
Relapsed vs. Refractory Multiple MyelomaVerywell Health
· Refractory Multiple Myeloma. Refractory is another word for resistant. Refractory myeloma is cancer that develops resistance to treatment or does not respond to it at all. There are two types of refractory myeloma Relapsed and refractory myeloma Myeloma that initially responds to treatment but then stops responding to it after a time or
Clinical Challenges Platinum-Resistant Ovarian Cancer
· Women with platinum-resistant or refractory relapsed epithelial ovarian cancer continue to have a poor prognosis and effective treatment of platinum resistance -- or even of preventing or
Estimated Reading Time 6 minsPlatinum-Resistant and Refractory Ovarian Cancer
· Patients with recurrent ovarian cancer who have a complete response to initial chemotherapy and a treatment-free interval <6 months demonstrate platinum resistance . 5 6 Refractory ovarian cancer is defined as stable or progressive disease during primary platinum-based therapy. 5 6 The difference between drug-sensitive and drug-resistant disease was initially described in relation
Understanding Recurrent or Progressive Ovarian Cancer
The Basics
NCI Dictionary of Cancer TermsNational Cancer Institute
· NCI s Dictionary of Cancer Terms provides easy-to-understand definitions for words and phrases related to cancer and medicine.
Management of Patients With Resistant or Refractory
23. O Hare T Walters DK Stoffregen EP et al In vitro activity of Bcr-Abl inhibitors AMN107 and BMS against clinically relevant imatinib-resistant Abl kinase domain mutants. Cancer Res 65 2005. 24. Deininger M Buchdunger E Druker BJ The development of imatinib as a therapeutic agent for chronic myeloid leukemia.
Therapeutic Options in Docetaxel-Refractory Metastatic
· Almost all patients become refractory to ADT and the disease becomes metastatic castration-resistant prostate cancer (mCRPC) for which docetaxel is the standard-of-care. Until recently there were few FDA-approved options for patients who progressed following docetaxel treatment except for mitoxantrone which improves quality-of-life through
Metastatic Castration-Resistant Prostate Cancer What s
· The term "castration resistant" refers to a cancer that is no longer responding to this type of therapy. According to the American Society of Clinical Oncology (ASCO) many men with prostate
Platinum-Resistant and Refractory Ovarian Cancer
· Patients with recurrent ovarian cancer who have a complete response to initial chemotherapy and a treatment-free interval <6 months demonstrate platinum resistance . 5 6 Refractory ovarian cancer is defined as stable or progressive disease during primary platinum-based therapy. 5 6 The difference between drug-sensitive and drug-resistant disease was initially described in relation
Castration-Resistant Prostate Cancer Treatment Outlook
· Castrate-resistant prostate cancer is prostate cancer that stops responding to hormone therapy. Hormone therapy also called androgen deprivation
platinum refractory Cancer Survivors Network
· In patients with relapsed ovarian cancer the overall response rates on treatment with topotecan range from 19 -33 in platinum-sensitive patients 14 -18 in platinum-resistant patients and 5 -11 in platinum-refractory patients. The proportion of patients achieving stable disease ranges between 17 in refractory and 48 in sensitive patients.
Avelumab in platinum-resistant/refractory ovarian cancer
· Women with PRROC ≤3 prior lines for platinum-sensitive disease and no prior therapy for platinum-resistant disease were randomized 1 1 1 to Ave (10 mg/kg Q2W) Ave PLD (40 mg/m 2 Q4W) or PLD. Pts were stratified by platinum status (refractory vs resistant) prior regimens (1 vs 2 or 3) and bulky disease (tumor ≥5 vs < 5 cm).
Author Kan Yonemori Takashi Matsumoto Shoji Nagao Noriyuki Katsumata Katsutoshi Oda Hidemichi Watari
Hormone-Refractory Prostate Cancer or Castrate-Resistant
· The Hormone Refractory Prostate Cancer (HRPCa) Association was a volunteer organization of one hundred men with HRPCa their family members and their caregivers that existed from 1999 to 2016. Members were from all over the U.S. Canada and the
What Is Relapsed vs. Refractory Myeloma The Myeloma
· Refractory Myeloma Dr. Damian Green MD of the Fred Hutchinson Cancer Center generally defines Refractory Myeloma as "disease that is progressing despite active treatment." The National Cancer Institute breaks it down even further to say that there are two main types of refractory
Refractory Metastatic Colorectal Cancer Current
· Introduction. Colorectal cancer (CRC) is a major global health issue being the third most commonly diagnosed malignancy with an estimated global incidence of over 1.8 million in 2018 predicted to increase to 2.2 million in 2030. 1 2 CRC is the second commonest cause of global cancer mortality with 0.5 million deaths in 2018 predicted to increase to 1.1 million by 2030. 1 2 Twenty percent of
Emerging Phase 3 Data in Relapsed/Refractory Metastatic
With its broad mechanism of action regorafenib can potentially suppress resistant clones not susceptible to a single drug with a single target. H O What data support the use of the newer agents RG The phase 3 RECOURSE (Study of TAS-102 in Patients With Metastatic Colorectal Cancer Refractory to Standard Chemotherapies) trial evaluated TAS-102
First-line Treatment for Metastatic Castrate-resistant
· Petrylak DP Tangen CM Hussain MH et al. Docetaxel and estramustine compared with mitoxantrone and prednisone for advanced refractory prostate cancer. N Engl J Med. Oct 7 (15) . Kantoff PW Higano CS Shore ND et al. Sipuleucel-T immunotherapy for castration-resistant prostate cancer. N Engl J Med. Jul 29 (5) .
platinum refractory Cancer Survivors Network
· In patients with relapsed ovarian cancer the overall response rates on treatment with topotecan range from 19 -33 in platinum-sensitive patients 14 -18 in platinum-resistant patients and 5 -11 in platinum-refractory patients. The proportion of patients achieving stable disease ranges between 17 in refractory and 48 in sensitive patients.
Treatment of platinum refractory or resistant ovarian cancer
· For instance whole-genome sequencing of DNA from high-grade ovarian serous tumours and germline DNA samples showed that CCNE1 amplification is common in primary resistant or refractory disease whereas acquired chemotherapy resistance is closely related to gene breakage inactivating tumour suppressor genes (RB1 NF1 RAD51B and PTEN) as well as independent reversions of germline BRCA1 or BRCA2 mutations loss of BRCA1 promoter methylation and
Cited by 1
Treatments for castrate-resistant prostate cancer
When cancer comes back or doesn t go away after hormonal therapy it is called castrate-resistant (hormone-refractory) prostate cancer. Your doctor will know that you have castrate-resistant prostate cancer if a blood test shows that your prostate-specific antigen (PSA) level
Therapeutic Options in Docetaxel-Refractory Metastatic
· Almost all patients become refractory to ADT and the disease becomes metastatic castration-resistant prostate cancer (mCRPC) for which docetaxel is the standard-of-care. Until recently there were few FDA-approved options for patients who progressed following docetaxel treatment except for mitoxantrone which improves quality-of-life through
Castration-Refractory Prostate Cancer New Therapies New
Resistance to androgen deprivation is an ominous milestone in the natural history of metastatic prostate cancer this disease state now referred to as castration-refractory prostate cancer (CRPC) is historically associated with a median survival of less than two years. Until recently only docetaxel (in combination with prednisone or estramustine) demonstrated a benefit in overall survival vs
Surgical Castration in Hormone-Refractory Metastatic
Background . Most patients with metastatic prostate cancer are endocrinologically treated with LHRH agonist but finally castration-refractory and hormone-refractory cancers occur. Serum testosterone levels get low to "the castration level" by LHRH agonists but may not get low enough against castration-refractory prostate cancer. Methods.
Hormone-Refractory Prostate Cancer or Castrate-Resistant
· The Hormone Refractory Prostate Cancer (HRPCa) Association was a volunteer organization of one hundred men with HRPCa their family members and their caregivers that existed from 1999 to 2016. Members were from all over the U.S. Canada and the
What are the treatment recommendations for platinum
· Cannistra SA Matulonis UA Penson RT Hambleton J Dupont J Mackey H. Phase II study of bevacizumab in patients with platinum-resistant ovarian cancer or peritoneal serous cancer
Chemotherapy vs Hormonal Treatment in Platinum-resistant
· Chemotherapy vs Hormonal Treatment in Platinum-resistant Ovarian Cancer Resistant or Refractory to Platinum and Taxane. The safety and scientific validity of this study is the responsibility of the study sponsor and investigators. Listing a study does not mean it has been evaluated by the U.S. Federal Government.
Castration-Refractory Prostate Cancer New Therapies New
Resistance to androgen deprivation is an ominous milestone in the natural history of metastatic prostate cancer this disease state now referred to as castration-refractory prostate cancer (CRPC) is historically associated with a median survival of less than two years. Until recently only docetaxel (in combination with prednisone or estramustine) demonstrated a benefit in overall survival vs
platinum refractory Cancer Survivors Network
· In patients with relapsed ovarian cancer the overall response rates on treatment with topotecan range from 19 -33 in platinum-sensitive patients 14 -18 in platinum-resistant patients and 5 -11 in platinum-refractory patients. The proportion of patients achieving stable disease ranges between 17 in refractory and 48 in sensitive patients.
Recurrent and Refractory Cancer Treatment Program
The Recurrent and Refractory Cancer Treatment Program is dedicated to working with patients whose cancers have recurred or are not responding to treatments. Our team specialists work with the Children s Oncology Group (COG) and other experts to offer patients
Hormone-Refractory Prostate Cancer or Castrate-Resistant
· The Hormone Refractory Prostate Cancer (HRPCa) Association was a volunteer organization of one hundred men with HRPCa their family members and their caregivers that existed from 1999 to 2016. Members were from all over the U.S. Canada and the
